Is Recursion Pharmaceuticals Stock a Buy?
Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum.
But does that make the stock worth buying right now, given the considerable uncertainties surrounding the actual merit of its AI-heavy approach? Let's dive in and figure it out.
For the uninitiated, Recursion wants to become the go-to provider of AI-based drug discovery and development services for the biopharmaceutical industry. It's also developing a handful of therapies for cancers and rare diseases with its in-house research and development (R&D) capabilities.
Source Fool.com
